We are live on ! Find out more
RGC icon

Regencell Bioscience
RGC

3 hedge funds and large institutions have $32.3K invested in Regencell Bioscience in 2022 Q4 according to their latest regulatory filings, with funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

2.06% less ownership

Funds ownership: 2.4% → 0.35% (-2.1%)

40% less funds holding

Funds holding: 5 → 3 (-2)

88% less capital invested

Capital invested by funds: $260K → $32.3K (-$228K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Holders
3
Holders Change
-2
Holders Change %
-40%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
2
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$3.52K
2
Morgan Stanley
Morgan Stanley
New York
+$1.57K

Top Sellers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
-$216K
2
TRCT
Tower Research Capital (TRC)
New York
-$12K
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS Group
1
UBS Group
Switzerland
$18.2K +$3.52K +4,598 +22%
Morgan Stanley
2
Morgan Stanley
New York
$7.64K +$1.57K +2,052 +24%
BlackRock
3
BlackRock
New York
$6.47K – – –
Geode Capital Management
4
Geode Capital Management
Massachusetts
– -$216K -259,008 Closed
TRCT
5
Tower Research Capital (TRC)
New York
– -$12K -14,136 Closed

RGC Hedge Fund Activity: Q4 2022 in Review

3 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Regencell Bioscience (RGC) for Q4 2022, worth a combined $32.3K — down 88% from $260K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of RGC and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 2 added.

The largest buyer was UBS Group, adding an estimated $3.52K. The largest seller was Geode Capital Management, exiting entirely with an estimated $216K sold.

  • 3 institutional investors held Regencell Bioscience (RGC) as of Q4 2022, down from 5 in Q3 2022.
  • Funds reported $32.3K of Regencell Bioscience stock for Q4 2022, down 88% quarter-over-quarter.
  • 0 funds opened new Regencell Bioscience positions in Q4 2022 and 2 closed out, a net change of -2 holders.
  • The largest Regencell Bioscience buyer in Q4 2022 was UBS Group, an estimated $3.52K added.
  • The largest Regencell Bioscience seller in Q4 2022 was Geode Capital Management, an estimated $216K sold.

Based on aggregated 13F filings for Q4 2022.